The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in
combination with nivolumab is safe and useful for patients with certain types of cancer. The
study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a
substantial improvement over other available therapies such as nivolumab alone. All eligible
patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.